Trials / Active Not Recruiting
Active Not RecruitingNCT06383052
A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Radiation Dosimetry and Efficacy of 177Lu-NYM032 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Norroy Bioscience Co., LTD · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
177Lu-NYM032 injection is a radioligand therapeutic agent that targets prostate specific membrane antigen (PSMA)-expressing prostate tumors. NYM032 is a small molecular with strong affinity for PSMA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 177Lu-NYM032 injection | Radionuclide 177Lu will be used as a therapeutic nuclide for this study. The precursor of NYM032 will be labeled with 177Lu to form the chelation product, 177Lu-NYM032 injection which will be used in this study as a intravenous injection dose of 177Lu-NYM032. The radiation dose is chosen within the range of 50-200 mCi for an individual patient at every dose. |
Timeline
- Start date
- 2024-04-26
- Primary completion
- 2025-06-30
- Completion
- 2026-06-30
- First posted
- 2024-04-25
- Last updated
- 2025-05-21
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06383052. Inclusion in this directory is not an endorsement.